Bispecific antibody · Immune activation, directed at CD3 (CD3E) and HIV-1 envelope glycoprotein gp120 · developed by MacroGenics
MGD014 is a bispecific DART molecule that binds the CD3 subunit of the T-cell receptor complex and the gp120 subunit of the HIV-1 envelope. It is studied in human immunodeficiency virus type 1 infection.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05261191 | Phase 1 | Human Immunodeficiency Virus I Infection | Completed | MGNX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Human Immunodeficiency Virus I InfectionHuman Immunodeficiency Virus Type 1Immunodeficiency Virus Type 1, Human
Updated Oct 18, 2026. Something wrong or missing? Report it on the MGNX page.
See MGNX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MGNX catalysts and pipeline →